Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Diseases of the Liver and Gallbladder

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Hepatic Drug Excretion: Influencing Factors

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial.

Gastroenterology·2026

Same author

What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association.

JHEP reports : innovation in hepatology·2022

Same author

Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial.

Canadian liver journal·2022

Same author

Reminiscences of a soon-to-be ex-hepatologist.

Canadian liver journal·2022

Same author

A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma.

Hepatology communications·2022

Same author

The viral hepatitis B care cascade: A population-based comparison of immigrant groups.

Hepatology (Baltimore, Md.)·2021

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Hepatocellular carcinoma: New and emerging risks.

Morris Sherman¹

¹Department of Medicine, University of Toronto and University Health Network, Toronto, ON M5N 2N2, Canada. morris.sherman@uhn.on.ca

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

|June 16, 2010

Summary

This summary is machine-generated.

Identifying hepatocellular carcinoma (HCC) risk factors beyond underlying liver disease is crucial. Factors like age, gender, and specific viral markers for hepatitis B and C help stratify patient risk for developing liver cancer.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 12, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

Hepatology and Oncology
Viral Hepatitis Research
Cancer Risk Factor Analysis

Background:

Hepatocellular carcinoma (HCC) development is linked to known liver diseases, but not all patients develop it.
Risk stratification within disease groups (e.g., hepatitis B, cirrhosis) is necessary to identify high-risk individuals.
Common risk factors include cellular dysplasia, advanced age, and male gender, while disease-specific factors are also significant.

Purpose of the Study:

To elucidate additional risk factors for hepatocellular carcinoma (HCC) beyond established underlying liver diseases.
To identify common and disease-specific markers that indicate varying HCC risk.
To explore emerging risk factors such as non-alcoholic fatty liver disease and diabetes.

Main Methods:

Analysis of large cohort studies to identify predictive markers for HCC development.
Evaluation of common risk indicators across different liver disease etiologies.
Investigation of disease-specific factors, particularly for hepatitis B and C.

Main Results:

Established common risk factors like age, gender, and dysplasia.
Identified hepatitis B viral load, genotype, and antigen status as key risk contributors.
Highlighted non-alcoholic fatty liver disease and diabetes as emerging HCC risk factors.

Conclusions:

Risk for hepatocellular carcinoma (HCC) is multifactorial, involving both general and disease-specific indicators.
Accurate risk assessment requires considering a combination of patient demographics, disease characteristics, and emerging factors.
Further research into non-alcoholic fatty liver disease and diabetes is warranted for HCC prevention strategies.